Literature DB >> 34666611

Knockdown of RREB1 inhibits cell proliferation via enhanced p16 expression in gastric cancer.

Qi Gao1,2,3, Yunhua Wu3, Chaoxiang Lu1,2, Wang Kai3, Weike Xie1,2, Qi Wang1,2, Lei Wang1,2, Shiqi Liu1,2, Yongkang Pan1,2.   

Abstract

Gastric cancer (GC) is the most common gastrointestinal malignancy worldwide. However, the molecular mechanisms of the progression of GC are not fully understood. Ras-responsive element binding protein 1 (RREB1) is an oncogene in many types of cancer that is involved in various biological processes, such as DNA damage repair, cell growth and proliferation, cell differentiation, fat development, and fasting glucose balance. In this study, we demonstrate the role of RREB1 in gastric cancer. First, by immunohistochemistry staining (IHC) and bioinformatics analysis, we demonstrated the expression of RREB1 in gastric cancer and paired normal gastric tissues. Then, we established RREB1 overexpression and knockdown cell lines via lentiviral transfection and detected cell proliferation by using MTT, colony-forming, cell cycle and apoptosis assays in vitro. We demonstrated the effect of RREB1 on cell proliferation in vivo by using a subcutaneous xenograft tumor model in nude mice. Finally, by using Western blotting and IHC, we demonstrated the possible mechanism by which RREB1 affects cell proliferation. The IHC and bioinformatics analyses demonstrated that RREB1 was highly expressed in gastric cancer and showed that RREB1-expressing patients had a larger tumor size and more lymphovascular invasion than RREB1-negative patients. Knockdown of RREB1 inhibited cell proliferation in vivo and in vitro. Knockdown of RREB1 enhanced p16 expression in vivo and in vitro, and p16 expression was negatively related to RREB1 in gastric cancer tissue. RREB1 was highly expressed in gastric cancer, and knockdown of RREB1 inhibited cell proliferation via enhanced p16 expression.

Entities:  

Keywords:  Gastric cancer; RREB1; cell proliferation; p16

Mesh:

Substances:

Year:  2021        PMID: 34666611      PMCID: PMC8794525          DOI: 10.1080/15384101.2021.1987676

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  25 in total

1.  RREB1 transcription factor splice variants in urologic cancer.

Authors:  Matthew D Nitz; Michael A Harding; Steven C Smith; Shibu Thomas; Dan Theodorescu
Journal:  Am J Pathol       Date:  2011-07       Impact factor: 4.307

Review 2.  [Research advances of K-ras mutation in the prognosis and targeted therapy of gastric cancer].

Authors:  Y Huang; J Wei; B R Liu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2016-02

3.  British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.

Authors:  Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro
Journal:  Gut       Date:  2019-07-05       Impact factor: 23.059

4.  RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets.

Authors:  O A Kent; K Fox-Talbot; M K Halushka
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

5.  RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas.

Authors:  A Thiagalingam; A De Bustros; M Borges; R Jasti; D Compton; L Diamond; M Mabry; D W Ball; S B Baylin; B D Nelkin
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

6.  Multidisciplinary Teams Improve Gastric Cancer Treatment Efficiency at a Large Safety Net Hospital.

Authors:  Michelle Ju; Sam C Wang; Samira Syed; Deepak Agrawal; Matthew R Porembka
Journal:  Ann Surg Oncol       Date:  2019-11-01       Impact factor: 5.344

7.  DNA damage signalling recruits RREB-1 to the p53 tumour suppressor promoter.

Authors:  Hanshao Liu; Hoi Chin Hew; Zheng-Guang Lu; Tomoko Yamaguchi; Yoshio Miki; Kiyotsugu Yoshida
Journal:  Biochem J       Date:  2009-08-27       Impact factor: 3.857

8.  TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1.

Authors:  Jie Su; Sophie M Morgani; Charles J David; Qiong Wang; Ekrem Emrah Er; Yun-Han Huang; Harihar Basnet; Yilong Zou; Weiping Shu; Rajesh K Soni; Ronald C Hendrickson; Anna-Katerina Hadjantonakis; Joan Massagué
Journal:  Nature       Date:  2020-01-08       Impact factor: 49.962

9.  Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway.

Authors:  Jun-Hui Yu; Jian-Bao Zheng; Jie Qi; Kui Yang; Yun-Hua Wu; Kai Wang; Chun-Bao Wang; Xue-Jun Sun
Journal:  Int J Oncol       Date:  2019-01-22       Impact factor: 5.650

10.  RREB1-induced upregulation of the lncRNA AGAP2-AS1 regulates the proliferation and migration of pancreatic cancer partly through suppressing ANKRD1 and ANGPTL4.

Authors:  Bingqing Hui; Hao Ji; Yetao Xu; Juan Wang; Zhonghua Ma; Chongguo Zhang; Keming Wang; Yan Zhou
Journal:  Cell Death Dis       Date:  2019-02-27       Impact factor: 8.469

View more
  1 in total

1.  Comparative expression analysis of tRF-3001a and tRF-1003 with corresponding miRNAs (miR-1260a and miR-4521) and their network analysis with breast cancer biomarkers.

Authors:  Shaharbhanu A Hussain; Kunhi Valappil Deepak; Dechamma Pandyanda Nanjappa; Viswanath Sherigar; Neetha Nandan; Padmanaban S Suresh; Thejaswini Venkatesh
Journal:  Mol Biol Rep       Date:  2021-10-18       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.